Andrew Ambrosy, MD
Cardiovascular Disease · Durham, NCNPI 1790084051
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $58,748 of the $71,638 with a category attached, or 82.0%. 15 manufacturers reported payments, led by Novo Nordisk AS at 34.2% of the total. 2025 is the largest year on record at $45,342, more than ten times the $272 reported in 2022. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 55 payments — averaging $1302.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$24K
- Novo Nordisk$22K
- Merck$13K
- E.r. Squibb & Sons, L.L.C.$5K
- Pfizer$4K
- Scpharmaceuticals Inc.$2K
- plus $910 from 9 others
Across 24 payments — averaging $132,410 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amarin Pharma, Inc.$2M
- Edwards Lifesciences$607K
- Esperion Therapeutics, Inc.$519K
- Bayer$36K
What the payments were for
- Consulting fees$58,74882%
- Travel & lodging$10,80615%
- Food & beverage$2,0853%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 7 | $24,470 |
| Novo Nordisk | 13 | $21,864 |
| Merck | 17 | $13,000 |
| E.r. Squibb & Sons, L.L.C. | 1 | $5,253 |
| Pfizer | 2 | $3,900 |
| Scpharmaceuticals Inc. | 4 | $2,242 |
| Abiomed | 1 | $203 |
| Boehringer Ingelheim | 1 | $193 |
| Novartis | 2 | $161 |
| Abbott | 1 | $152 |
| AstraZeneca | 2 | $53 |
| American Regent | 1 | $49 |
| Cvrx, Inc. | 1 | $39 |
| Lexicon Pharmaceuticals, Inc. | 1 | $33 |
| Esperion Therapeutics, Inc. | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$71,638 in reported general payments places this provider in the 90th percentile of 727 cardiovascular disease providers in North Carolina.
See all cardiovascular disease providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 15 | $9,011 |
| Amiodarone Hcl | 16 | $480 |
| Atorvastatin Calcium | 38 | $443 |
| Carvedilol | 37 | $416 |
| Metoprolol Succinate | 31 | $375 |
| Flecainide Acetate | 12 | $346 |
| Amlodipine Besylate | 16 | $214 |
| Torsemide | 12 | $173 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Durham
- R WilliamsDurham$2.1M
- Marat FudimDurham$902K
- Jonathan PicciniDurham$767K
- Robert MentzDurham$489K
- Adrian HernandezDurham$409K
- Neha PagidipatiDurham$301K
- Joseph KissloDurham$283K
- Mitchell KrucoffDurham$281K
- Ankeet BhattDurham$258K
- Christopher GrangerDurham$257K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.